TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07809906: Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

Sponsor: Orum Therapeutics USA, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07809906 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07809906 Rescue Dossier →